CELLULAR DYNAMICS INTERNATIONAL, INC.
Induced pluripotent stem cell (iPSC) services and products for research and manufacturing
- Sector
- Biotech
- Headquarters
- MADISON, WI
- Founded
- 2007
- Latest Form D
- $20M, Jul 2013
- Total capital
- $102M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $102M
- 4 Form D · last Jul 2013
- 160 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2016
- Rank in peer group#22 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$20M
- Private capital raisedForm D · SEC · 3rd filing$21M
- Private capital raisedForm D · SEC · 2nd filing$30M
- Private capital raisedForm D · SEC · 1st filing$31.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#22 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- James A. ThomsonResearcherDirector, PromoterLinked by 1 patent
- Christopher A. Kendrick-ParkerExecutive OfficerNamed in SEC Form D filings
- Christopher A. ParkerExecutive OfficerNamed in SEC Form D filings
- Craig T. JanuaryDirectorNamed in SEC Form D filings
- David A. SnyderExecutive OfficerNamed in SEC Form D filings
- Emile A. NuwaysirExecutive OfficerNamed in SEC Form D filings
Show all 16 people
- Gregory C. LynchDirectorNamed in SEC Form D filings
- Kenneth C. HuntDirectorNamed in SEC Form D filings
- Leonard T. LoventhalDirectorNamed in SEC Form D filings
- Michael A. FalkDirectorNamed in SEC Form D filings
- Michael J. Van HandelDirectorNamed in SEC Form D filings
- Nicholas A. SeayExecutive OfficerNamed in SEC Form D filings
- Robert J. PalayExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Sheli Z. RosenbergDirectorNamed in SEC Form D filings
- Stanley C. RoseDirectorNamed in SEC Form D filings
- Thomas M. PalayExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- PendingMethod For Reproducible Differentiation Of Clinical-grade Retinal Pigment Epithelium CellsUSPTOApplication 15758314
- GrantedReprogramming T Cells And Hematopoietic CellsUSPTOUS 10,221,396
- GrantedCardiomyocyte ProductionUSPTOUS 9,957,482
Show all 40 patent records
- Method For Reproducible Differentiation Of Clinical-grade Retinal Pigment Epithelium CellsJun 6, 2019 · Application 15758314Pending
- Reprogramming T Cells And Hematopoietic CellsMar 5, 2019 · US 10,221,396Granted
- Cardiomyocyte ProductionMay 1, 2018 · US 9,957,482Granted
- Production Of Midbrain Dopaminergic Neurons And Methods For The Use ThereofJul 4, 2017 · US 9,694,036Granted
- Mouse Model For Engraftment PotentialJun 6, 2017 · US 9,668,463Granted
- Methods For The Production Of Ips Cells Using Epstein-barr (ebv)-based Reprogramming VectorsMay 9, 2017 · US 9,644,184Granted
- Hepatocyte Production Via Forward Programming By Combined Genetic And Chemical EngineeringApr 20, 2017 · Application 15305650Pending
- Methods For Cell Reprogramming And Genome EngineeringSep 29, 2016 · Application 15051541Pending
- Generation Of Induced Pluripotent Stem Cells From Small Volumes Of Peripheral BloodSep 20, 2016 · US 9,447,382Granted
- Reprogramming T Cells And Hematopoietic CellsSep 8, 2016 · Application 15139746Pending
- Endothelial Cell Production By ProgrammingAug 2, 2016 · US 9,404,122Granted
- Cardiomyocyte ProductionJun 14, 2016 · US 9,365,827Granted
- Episomal Reprogramming With ChemicalsMay 26, 2016 · Application 15006970Pending
- Reprogramming T Cells And Hematopoietic CellsMay 24, 2016 · US 9,347,044Granted
- Methods For The Production Of Ips Cells Using Non-viral ApproachMay 3, 2016 · US 9,328,332Granted
- Hepatocyte Production By Forward ProgrammingFeb 16, 2016 · US 9,260,722Granted
- Compendium Of Ready-built Stem Cell Models For Interrogation Of Biological ResponseAug 6, 2015 · Application 14597081Pending
- Reprogramming Immortalized B CellsNov 27, 2014 · Application 14284283Pending
- Hepatocyte Production Via Forward Programming By Combined Genetic And Chemical EngineeringAug 28, 2014 · Application 14186620Pending
- Automated Method And Apparatus For Embryonic Stem Cell CultureNov 28, 2013 · Application 13847349Pending
- Cardiomyocyte ProductionAug 1, 2013 · Application 13794679Pending
- Methods And Compositions For Culturing Endoderm Progenitor Cells In SuspensionApplication PCTUS2014032804Pending
- Hepatocyte Production Via Forward Programming By Combined Genetic And Chemical EngineeringApplication PCTUS2014017588Pending
- Hepatocyte Production Via Forward Programming By Combined Genetic And Chemical EngineeringApplication 61768301Pending
- Metabolic Maturation In Stem Cell-derived Tissue CellsApplication PCTUS2012048653Pending
- Methods For Cell Reprogramming And Genome EngineeringApplication PCTUS2012046194Pending
- Priming Of Pluripotent Stem Cells For Neural DifferentiationApplication PCTUS2012031457Pending
- Hematopoietic Precursor Cell Production By ProgrammingApplication PCTUS2012024098Pending
- Reprogramming Immortalized B CellsApplication PCTUS2011046452Pending
- Endothelial Cell Production By ProgrammingApplication PCTUS2011043218Pending
- Cardiomyocyte Medium With Dialyzed SerumApplication PCTUS2011041103Pending
- A Compendium Of Ready-built Stem Cell Models For Interrogation Of Biological ResponseApplication PCTUS2011040519Pending
- Generation Of Induced Pluripotent Stem Cells From Small Volumes Of Peripheral BloodApplication PCTUS2011040323Pending
- Hepatocyte Production By Forward ProgrammingApplication PCTUS2011032309Pending
- Episomal Reprogramming With ChemicalsApplication PCTUS2010055444Pending
- Identifying Genetic Variation In Affected TissuesApplication PCTUS2010046735Pending
- Modified Ips Cells Having A Mutant Form Of Human Immunodeficiency Virus (hiv) Cellular Entry GeneApplication PCTUS2010041194Pending
- Reprogramming T Cells And Hematophietic CellsApplication PCTUS2010037376Pending
- Differentiation Of Pluripotent CellsApplication PCTUS2010025776Pending
- Methods And Compositions For The Differentiation Of Stem CellsApplication PCTUS2010024881Pending
Related companies, and why
- Bambusa TherapeuticsSimilar federal contract value in Biotech · null in contracts
- IMMUNOMATICS, INC.Similar federal contract value in Biotech · null in contracts
- Secura Bio Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Delix TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Magenta TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Vor BiopharmaSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .